Intelligent Bio Solutions Inc.
INBS Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$1.64
KIRA · Stoqly’s AI analyst, in plain words
- Intelligent Bio Solutions Inc. had $4.2M of revenue in fiscal 2026, up 38.1% on the year before. Over five years, revenue changed +16.3% a year on average.
- Its operating margin was −299.1%, up 50.7 pts: of every 100 in sales, about −299 is left after running the business.
- Intelligent Bio Solutions Inc. lost $12.4M in fiscal 2026.
- Free cash flow was −$12.1M in fiscal 2026, −285.9% of revenue.
Market cap
$2.4M
P/E
—
Revenue
$4.2M
Net income
−$12.4M
Free cash flow
−$12.1M
Operating margin
−299.1%
Intelligent Bio Solutions Inc. in 30 seconds · fiscal 2026
Are sales growing?
+38.1%
Yes. Sales grew 38.1% last year.
Does it make a profit?
−294.9%
No. It lost money last year.
Does profit turn into cash?
−285.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Intelligent Bio Solutions Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Aug 19, 2026
- Legal name
- INTELLIGENT BIO SOLUTIONS INC.
- CIK
- 0001725430
Intelligent Bio Solutions Inc. · INBS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.4M | $1.3M | $3.1M | $3.1M | $4.2M |
| Revenue growth | −77.9% | 187.6% | 147.6% | −1.9% | 38.1% |
| Gross margin | — | 26.0% | 45.8% | 40.8% | 48.6% |
| Operating margin | −1,907.3% | −1,002.1% | −330.5% | −349.9% | −299.1% |
| Net income | −$8.3M | −$10.6M | −$10.2M | −$10.6M | −$12.4M |
| Net margin | −1,900.3% | −845.9% | −326.4% | −346.2% | −294.9% |
| Diluted EPS | −$11.33 | −$127.00 | −$6.38 | −$20.04 | −$8.44 |
| Cash | |||||
| Cash from operations | −$3.4M | −$7.4M | −$9.6M | −$9.7M | −$11.9M |
| Capital expenditure | — | — | $0.2M | $0.2M | $0.1M |
| Free cash flow | — | — | −$9.8M | −$9.9M | −$12.1M |
| FCF margin | — | — | −314.7% | −324.6% | −285.9% |
| Share count change | −93.0% | −88.6% | 1,802.9% | −66.9% | 179.2% |
| Debt and strength | |||||
| Cash and short-term investments | $8.2M | $1.5M | $6.3M | $1.0M | $4.0M |
| Shareholders' equity | $6.6M | $3.8M | $8.3M | $3.0M | $5.5M |
| Current ratio | 2.3x | 0.7x | 1.6x | 0.8x | 1.4x |
| Interest coverage | — | — | −61.5x | −406.1x | −1,178.3x |
| Returns and quality | |||||
| Return on equity | −76.6% | −204.0% | −167.5% | −186.6% | −292.3% |
| Return on tangible equity | −125.4% | — | −256.7% | — | −458.4% |
| Piotroski F-score | 2 | 3 | 5 | 3 | 4 |
| Altman Z'' | −8.3 | −22.0 | −14.3 | −33.8 | −25.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Intelligent Bio Solutions Inc. · INBS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.64 a share, the company is worth $2.4M.
Source: SEC EDGAR XBRL filings (CIK 0001725430). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.